Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB)

$5.63
-0.02 (-0.35 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$5.54
Now: $5.63
$5.6650
50-Day Range
$5.30
MA: $5.60
$5.90
52-Week Range
$3.90
Now: $5.63
$7.84
Volume759,667 shs
Average Volume1.33 million shs
Market Capitalization$861.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$78.63 million
Book Value$0.76 per share

Profitability

Net Income$-102,560,000.00
Net Margins-140.68%

Miscellaneous

Employees401
Market Cap$861.16 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.


Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The biotechnology company had revenue of $24.62 million for the quarter, compared to the consensus estimate of $22.27 million. Pacific Biosciences of California had a negative return on equity of 106.36% and a negative net margin of 140.68%. View Pacific Biosciences of California's Earnings History.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Pacific Biosciences of California.

What price target have analysts set for PACB?

3 Wall Street analysts have issued twelve-month price targets for Pacific Biosciences of California's stock. Their predictions range from $6.50 to $8.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $7.50 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.

What is the consensus analysts' recommendation for Pacific Biosciences of California?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.

What are Wall Street analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:
  • 1. According to Zacks Investment Research, "Pacific Biosciences exited the first quarter on a weak note. While loss per share widened, the top line missed the consensus mark. The company has been gaining ground in the MedTech space on strong Sequel performance, which saw record bookings. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the acquisition of the former for $8 per Pacific Biosciences share (in an all-cash transaction). Per management, the total value of the deal is approximately $1.2 billion. The agreement is expected to close by mid-2019. Reflective of these, the company has outperformed its industry in a year’s time. On the flip side, both Product and Services revenues declined year over year. Significant contraction in gross margin and rise in operating expenses are concerning. The DNA sequencing market is fraught with competition." (5/21/2019)
  • 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019)

Has Pacific Biosciences of California been receiving favorable news coverage?

News coverage about PACB stock has been trending negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Pacific Biosciences of California.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Novavax (NVAX), CenterPoint Energy (CNP), Alkaline Water (WTER), FireEye (FEYE), bluebird bio (BLUE), EXACT Sciences (EXAS), Gilead Sciences (Gild), Alphabet (GOOG) and JD.Com (JD).

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
  • Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 51)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.65%), Magnetar Financial LLC (5.19%), Vanguard Group Inc. (5.01%), Alpine Associates Management Inc. (3.97%), ARP Americas LP (2.87%) and Water Island Capital LLC (2.54%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Balyasny Asset Management LLC, Marshall Wace LLP, Stansberry Asset Management LLC, JPMorgan Chase & Co., Oracle Investment Management Inc., SG Americas Securities LLC and Magnetar Financial LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was acquired by a variety of institutional investors in the last quarter, including ARP Americas LP, Grantham Mayo Van Otterloo & Co. LLC, BNP Paribas Arbitrage SA, Man Group plc, BlackRock Inc., Nuveen Asset Management LLC, Polar Asset Management Partners Inc. and Polar Asset Management Partners Inc.. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $5.63.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $861.16 million and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is http://www.pacb.com/.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel